Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Savient Pharmaceuticals, Inc. (the "Registrant") was advised by the NASDAQ Stock Market LLC (the "Staff") that it did not comply with Listing Rule 5605(e) (the "Rule") which requires independent director oversight of director nominations. On May 2, 2012, the Registrant subsequently notified the Staff that its Board of Directors reconstituted its Nominating and Corporate Governance Committee to be comprised solely of independent directors. Accordingly, the Staff notified the Registrant on May 4, 2012 that it has determined that the Registrant regained compliance with the Rule and that this matter is closed upon the filing of this Current Report on Form 8-K.

---